Personal clinical trials search tool
If you would like to receive automatic trial alerts to your inbox or to change your alert preferences click here.
Your search criteria - 48 result(s)
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
The Ottawa Hospital, Ottawa, Ontario – Recruiting
Collection of Tissue Samples for Cancer Research
Study phase:
Recruitment status: Recruiting
Princess Margaret Hospital Cancer Centre, Toronto, – Completed
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Tom Baker Cancer Center/Alberta Health Services, Calgary, Alberta – Completed
Cross Cancer Institute / University of Alberta, Edmonton, Alberta – Completed
Vancouver General Hospital, Vancouver, British Columbia – Completed
Other Centres
Cancer Care Manitoba, Winnipeg, Manitoba – (active not recruiting)
Memorial Hospital of Newfoundland, St. John's, Newfoundland and Labrador – Completed
Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia – (active not recruiting)
Princess Margaret Cancer Centre, Toronto, Ontario – (active not recruiting)
Maisonneuve-Rosemont Hospital, Montreal, Quebec – Completed
Royal Victoria Hospital / McGill University, Montreal, Quebec – Completed
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Study phase: Phase 2
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
BCCA - Kelowna, Kelowna, British Columbia – Recruiting
BCCA - Vancouver, Vancouver, British Columbia – Recruiting
Other Centres
Kingston Health Sciences Centre, Kingston, Ontario – Recruiting
London Health Sciences Centre Research Inc., London, Ontario – Recruiting
Ottawa Hospital Research Institute, Ottawa, Ontario – Recruiting
University Health Network, Toronto, Ontario – Recruiting
The Jewish General Hospital, Montreal, Quebec – Recruiting
Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting
Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Study phase:
Recruitment status: Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients
Study phase: N/A
Recruitment status: Recruiting
London Health Sciences Centre-Victoria Hospital, London, Ontario – Recruiting
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Study phase: Phase 2
Recruitment status: Recruiting
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Tom Baker Cancer Center, Calgary, Alberta – Recruiting
University of Alberta, Edmonton, – Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Study phase: Phase 3
Recruitment status: Recruiting
CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec – (active not recruiting)
Saskatoon Cancer Center, Saskatoon, Saskatchewan – Recruiting
Early Integration of Palliative and Supportive Care in Cellular Therapy
Study phase: N/A
Recruitment status: Recruiting
Tom Baker Cancer Centre, Calgary, Alberta – Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Study phase: Phase 3
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, – Recruiting
QEII Health Sciences Centre, Halifax, – Recruiting
The Ottawa General Hospital, Ottawa, – Recruiting
Other Centres
Saskatoon Cancer Center, Saskatoon, – Recruiting
"Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)", Sherbrooke, – Recruiting
Princess Margaret Cancer Centre, Toronto, – Recruiting
BC Cancer, Vancouver, – Recruiting
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Study phase: Phase 2
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
NL Health Services, St. John's, Newfoundland and Labrador – Recruiting
QEII Health Science Centre, Halifax, Nova Scotia – Recruiting
Other Centres
London Health Sciences Centre, London, Ontario – Recruiting
Princess Margaret Hospital, Toronto, Ontario – Recruiting
Hôpital Maisonneuve-Rosemont, Montreal, Quebec – Recruiting
McGill University Health Centre, Montreal, Quebec – Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary, Alberta – Recruiting
University of Alberta - Cross Cancer Institute, Edmonton, Alberta – Recruiting
University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario – Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Study phase: Phase 3
Recruitment status: Recruiting
Local Institution - 0225, Greenfield Park, Quebec – (active not recruiting)
Local Institution - 0174, Montreal, Quebec – (active not recruiting)
Local Institution - 0222, Québec, Quebec – (active not recruiting)
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Study phase:
Recruitment status: Recruiting
Jewish General Hospital, Montreal, Quebec – Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
Cross Cancer Institute, Edmonton, Alberta – Completed
British Columbia Cancer Agency, Vancouver, British Columbia – Recruiting
Other Centres
Lakeridge Health Oshawa, Oshawa, Ontario – Recruiting
CHU de Quebec L Hotel Dieu de Quebec, Québec, Quebec – Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Study phase: Phase 3
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Not yet recruiting
Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Not yet recruiting
QEII Health Sciences Centre, Halifax, Nova Scotia – Recruiting
Other Centres
Nova Scotia Health Authority, Halifax, Nova Scotia – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Study phase:
Recruitment status: Recruiting
Edith Pituskin, Edmonton, Alberta – Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
Juravinski Cancer Centre /ID# 252053, Hamilton, Ontario – Recruiting
Ottawa Hospital Research Institute /ID# 252151, Ottawa, Ontario – Completed
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital), Toronto, Ontario – Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
The Ottawa Hospital Cancer Centre, Ottawa, Ontario – (active not recruiting)
Sunnybrook Health Sciences Centre, Toronto, Ontario – (active not recruiting)
University Health Network-Princess Margaret Cancer Center, Toronto, Ontario – (active not recruiting)
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Study phase: Phase 4
Recruitment status: Recruiting
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
McGill University Health Centre, Montreal, Quebec – Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Research Site, Hamilton, Ontario – Recruiting
Research Site, Ottawa, Ontario – Recruiting
Research Site, Toronto, Ontario – Not yet recruiting
Other Centres
Research Site, Montreal, Quebec – Recruiting
Research Site, Nova Scotia, – Not yet recruiting
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Study phase: Phase 3
Recruitment status: Recruiting
The Moncton Hospital, Moncton, New Brunswick – Recruiting
Jewish General Hospital, Montreal, Quebec – Recruiting
Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎ, Montreal, Quebec – Recruiting
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
University Health Network_Princess Margaret Cancer Centre /ID# 261566, Toronto, Ontario – Completed
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
BCCA - Kelowna, Kelowna, British Columbia – Recruiting
BCCA - Vancouver, Vancouver, British Columbia – Recruiting
Other Centres
CancerCare Manitoba, Winnipeg, Manitoba – Recruiting
The Moncton Hospital, Moncton, New Brunswick – Recruiting
Regional Health Authority B, Zone 2, Saint John, New Brunswick – Recruiting
Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador – Recruiting
Royal Victoria Regional Health Centre, Barrie, Ontario – Recruiting
William Osler Health System, Brampton, Ontario – Recruiting
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario – Recruiting
Kingston Health Sciences Centre, Kingston, Ontario – Recruiting
Waterloo Regional Health Network (WRHN), Kitchener, Ontario – Recruiting
London Health Sciences Centre Research Inc., London, Ontario – Recruiting
Stronach Regional Health Centre at Southlake, Newmarket, Ontario – Recruiting
Lakeridge Health Oshawa, Oshawa, Ontario – Recruiting
Ottawa Hospital Research Institute, Ottawa, Ontario – Recruiting
Algoma District Cancer Program, Sault Ste. Marie, Ontario – Recruiting
Niagara Health System, St. Catharines, Ontario – Recruiting
St. Michael's Hospital, Toronto, Ontario – Recruiting
St. Joseph's Health Centre, Toronto, Ontario – Recruiting
Windsor Regional Cancer Centre, Windsor, Ontario – Recruiting
CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec – Recruiting
The Jewish General Hospital, Montreal, Quebec – Recruiting
St. Mary's Hospital, Montreal, Quebec – Recruiting
The Research Institute of the McGill University, Montreal, Quebec – Recruiting
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec, Quebec – Recruiting
Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting
Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Study phase: Phase 3
Recruitment status: Recruiting
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta – (active not recruiting)
British Columbia Cancer Agency, Vancouver, British Columbia – (active not recruiting)
Nova Scotia Health Authority, Halifax, Nova Scotia – (active not recruiting)
Other Centres
Juravinski Cancer Centre, Hamilton, Ontario – (active not recruiting)
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – (active not recruiting)
CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal, Quebec – (active not recruiting)
Saskatoon Cancer Centre, Saskatoon, Saskatchewan – (active not recruiting)
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Study phase: Phase 1
Recruitment status: Recruiting
Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Recruiting
CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec – Recruiting
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer, Sherbrooke, Quebec – Recruiting
Plan Development for Giving Teclistamab in the Outpatient Setting
Study phase: Phase 4
Recruitment status: Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
Study phase: N/A
Recruitment status: Recruiting
University of Alberta/ Cross Cancer Institute, Edmonton, Alberta – Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 2
Recruitment status: Recruiting
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
McGill University Health Centre, Montreal, Quebec – Recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Study phase: Phase 3
Recruitment status: Recruiting
Local Institution - 0133, Edmonton, Alberta – Not yet recruiting
Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Recruiting
Local Institution - 0134, Montreal, Quebec – Not yet recruiting
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Study phase: Phase 2
Recruitment status: Recruiting
Vancouver Cancer Center, Vancouver, British Columbia – Recruiting
Juravinski Cancer Center, Hamilton, Ontario – Recruiting
Kingston General Hospital, Kingston, Ontario – Recruiting
Other Centres
London Health Science Centre - Victoria Hospital, London, Ontario – Recruiting
London Health Science Centre - Victoria Hospital, London, Ontario – Recruiting
Ottawa Hospital, Ottawa, Ontario – Recruiting
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Study phase: N/A
Recruitment status: Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Study phase: Phase 3
Recruitment status: Recruiting
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
Vancouver General Hospital, Vancouver, British Columbia – Recruiting
QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Recruiting
Other Centres
Local Institution - 0192, Hamilton, Ontario – Not yet recruiting
CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec – Recruiting
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
Investigational Site Number : 1240005, Vancouver, British Columbia – Recruiting
Investigational Site Number : 1240001, Montreal, Quebec – Recruiting
Investigational Site Number : 1240002, Sherbrooke, Quebec – Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Study phase: Phase 3
Recruitment status: Recruiting
GSK Investigational Site, Saint John, New Brunswick – Recruiting
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Study phase: N/A
Recruitment status: Not yet recruiting
Centre de Recherche de l'Hôpital Maissonneuve-Rosemont, Montréal, Quebec – ()
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Study phase: N/A
Recruitment status: Recruiting
University Health Network, Toronto, Ontario – Recruiting
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
University Health Network_Princess Margaret Cancer Centre /ID# 275636, Toronto, Ontario – Recruiting
Jewish General Hospital /ID# 267574, Montreal, Quebec – Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec – Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
Local Institution - 0026, Vancouver, British Columbia – Not yet recruiting
QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Recruiting
Other Centres
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Study phase: Phase 4
Recruitment status: Recruiting
Centre Intégré de Cancérologie, Québec, Quebec – Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting
British Columbia Cancer Agency, Vancouver, British Columbia – Recruiting
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia – Recruiting
Other Centres
Juravinski Cancer Centre, Hamilton, Ontario – Recruiting
London Health Sciences Centre, London, Ontario – Recruiting
University Health Network UHN Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal, Quebec – Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Study phase: Phase 3
Recruitment status: Recruiting
Research Site, Calgary, Alberta – Not yet recruiting
Research Site, Vancouver, British Columbia – Not yet recruiting
Research Site, Toronto, Ontario – Not yet recruiting
Other Centres
Research Site, Montreal, Quebec – Not yet recruiting
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting